Compare Abeona Therapeutics Inc (ABEO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Warner Music Group Corp — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while Warner Music Group Corp trades at $25.13 (market cap $13.12B). The key difference: Warner Music Group Corp is far larger — about 31.1× Abeona Therapeutics Inc's market cap, and Warner Music Group Corp pays a 3.19% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WMG | |
|---|---|---|
Market Cap | $421.19M | $13.12B |
Sector | Health | Media |
52-Week High | $7.45 | $34.72 |
52-Week Low | $4.17 | $23.65 |
Enterprise Value | $276.10M | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Warner Music Group (WMG) trades at $26.41, up 0.08% on the day, with a bearish technical signal but improving fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $7.3B projected for 2026. The stock shows a P/E of 20.06 and net income margin of 9.2%, supported by strong cash flow and dividend payments. Key resistance is at $27, with support at $26.
WMG presents a mixed outlook: bullish fundamentals with earnings beats and growth, but technicals indicate near-term pressure. Opportunities include streaming expansion and AI integration, while risks involve leadership changes and market volatility. Analyst consensus is 66.7% buy, suggesting long-term value if technical resistance is overcome.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
